DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

Post-LOE

dexbrompheniramine maleate; pseudoephedrine sulfate

Merck & Co.

ANDAORALTABLET, EXTENDED RELEASE

Approved

Feb 2013

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE (dexbrompheniramine maleate; pseudoephedrine sulfate) by Merck & Co.. Approved for nasal congestion due to the common cold, hay fever, other upper repiratory allergies helps decongest sinus opening and 5 more indications. First approved in 2013.

Drug data last refreshed 23h ago

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications (8)

nasal congestion due to the common cold hay fever

Worked on DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.